SCHEMBL14729658

SCHEMBL14729658

Fc1ccc(-c2cc(OCc3ccccc3)c(OCc3ccccc3)nn2)c(F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPIA P62937 1/20 0.43
L3MBTL1 Q9Y468 3/20 0.42
KDM1A O60341 1/20 0.41
PTGER1 P34995 2/20 0.41
GRM5 P41594 2/20 0.41
FEN1 P39748 2/20 0.41
CCNT1 O60563 1/20 0.41
CCNA2 P20248 1/20 0.41
CDK2 P24941 1/20 0.41
CDK9 P50750 1/20 0.41
CCNA1 P78396 1/20 0.41
BRD4 O60885 2/20 0.40
TP53 P04637 1/20 0.40
MDM2 Q00987 1/20 0.40
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
MAPK1 P28482 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14729678 0.88 PTGER1 (0.46) L3MBTL1KDM1APTGER1FEN1BRD4
SCHEMBL14729682 0.85 RXRA (0.47) PPIAPTGER1FEN1CYP11B1CYP11B2
SCHEMBL14729677 0.82 SMN1; SMN2 (0.45) L3MBTL1PTGER1BRD4TP53LMNA
SCHEMBL16231698 0.81 FFAR1 (0.46) PPIAL3MBTL1KDM1APTGER1LMNA
SCHEMBL14729690 0.80 EGFR (0.45) L3MBTL1PTGER1LMNAMAPTMAPK1
SCHEMBL14729715 0.80 KDM1A (0.46) L3MBTL1KDM1APTGER1BRD4MAPT
SCHEMBL14718804 0.78 PPIA (0.40) PPIAL3MBTL1KDM1APTGER1BRD4
SCHEMBL14729696 0.77 MAOB (0.43) KDM1APTGER1FEN1LMNANPC1
SCHEMBL14729707 0.77 SQOR (0.51) L3MBTL1PTGER1BRD4CYP11B1CYP11B2
SCHEMBL14729662 0.77 BRD4 (0.43) PTGER1BRD4TP53MAPK1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013027000-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-02-28 WO disclosed
US-20130052281-A1 NOVEL COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130052281-A1 NOVEL COMPOUNDS ABCG2, F12, UGT1A1 PPIA 4300/4885L3MBTL1 4060/4885KDM1A 3048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.